

PTO/SB/30 (08-00)
Approved for use through 10/31/2002. ØMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT/OF COMMERCE

work Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid GMB control number.

REQUEST **FOR**

CONTINUED EXAMINATION (RCE) TRANSMITTAL

Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, provides for continued examination of an utility or plant application filed on or after June 8, 1995. See The American Inventors Protection Act of 1999 (AIPA).

Application Number	09/676,090			
Filing Date	October 2, 2000			
First Named Inventor	TAKAO OGURA '			
Group Art Unit	1745			
Examiner Name	John S. Maples			
Attorney Docket Number	00839.000438			

This	NOTE: filing a contin of the AIPA	est for Continued Examination (RCE) under 37 C.F.R. 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identity nued prosecution application (CPA) under 37 C.F.R. § 1.53(d) (PTC See Changes to Application Examination and Provisional Application (Mar. 20, 2000), 1233 Off. Gaz. Pat. Office 47 (Apr. 11, 2000), which	fied application D/SB/29) instead ion Practice, Fin	was filed prior to May 29, 2000, a f of a RCE to be eligible for the pa al Rule, 65 Fed. Reg. 50092 (Aut	applicant may wish to consider atent term adjustment provisions			
1.	Submission	on required under 37 C.F.R. § 1.114						
	a. 🗆	Previously submitted						
l	i.	i Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on						
	ii.	ii. (Any unentered amendment(s) referred to above will be entered). Consider the arguments in the Appeal Brief or Reply Brief previously filed on						
	iii. Other							
	b. 🗓	iii. Other						
	b. X Enclosed i. Amendment/Reply ii. Affidavit(s)/Declaration(s) iii X Information Bioglogyus Statement (IDS)							
	ii. Affidavit(s)/Declaration(s)							
	iii. X Information Disclosure Statement (IDS)							
	iv. LXJ Other European Search Report							
2.	Miscellan				100()			
	a. Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103(c) for a period of							
	months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(i) required)							
١,		Other The RCE fee under 37 C.F.R. § 1.17(e) is required by 37 C.F.R. § 1.114 when the RCE is filed.						
3.	1 003	1003						
		The Director is hereby authorized to charge any deficiencies in the following fees, or credit any overpayments, to Deposit Account No. 06-1205						
			01/29	/2003 ANDNDAF1 00000144 (09676090			
	i. ii.	X RCE fee required under 37 C.F.R. § 1.17(e) Extension of time fee (37 C.F.R. §§ 1.136 and 1.17) 01 FC:1801 750.00 0P						
	iii. Other							
	b. 🗓	Check in the amount of \$ 750.00 enclosed						
	c. Payment by credit card (Form PTO-2038 enclosed)							
		SIGNATURE OF APPLICANT, ATTO	ORNEY, OR AG	SENT REQUIRED				
Nan	Name (Print/Type) Michael K. O'Mpill		Registration	No. (Attorney/Agent)	32,622			
Sigr	nature	+ Wickard K Orbins	Date	January 21, 2003				
		CERTIFICATE OF MAILIN	G OR TRANSM	ISSION				
		this correspondence is being deposited with the United States Pos Patents, Box RCE, Washington, DC 20231, or facsimile transmitted						
Nar	ne (<i>Print/Typ</i>	1110111101						
	Signature Date January 21, 2003 Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any							

comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND Fees and Completed Forms to the following address: Commissioner for Patents, Box RCE, Washington, DC 20231.